Amniotic Products Market - Research Report 2022-2028

[Research Report] The amniotic products market is expected to grow from US$ 1,164.32 million in 2022 to US$ 1,889.07 million by 2028. It is estimated to grow at a CAGR of 8.4% from 2022 to 2028.

Traumatic wounds are a significant clinical, social, and economic burden because of the rising healthcare expenditures, an aging population, identification of difficult-to-treat infection risks such as biofilms, and the global hazard of diabetes and obesity. Traumatic wounds are those that have not proceeded through the normal healing process and have been open for longer than a month. In comparison to the overall burden of chronic wounds as a health care concern, research funding dedicated to studying chronic wounds is disproportionately low. Wound healing using amniotic membrane grafts has some therapeutic potential. Early use of an amniotic membrane for ulcers, burns, and cutaneous injuries proved therapeutic. Therefore, an increasing number of traumatic wounds is boosting the amniotic product market.

The amniotic products market is analyzed into type, application, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. This report offers insights and in-depth analysis of the market, emphasizing parameters, such as market trends, market dynamics, and the competitive analysis of the globally leading market players.  

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Amniotic Products Market: Strategic Insights

Amniotic Products Market

• 
  CAGR (2022 - 2028)

  8.4%
• Market Size 2022
  US$ 1.16 Billion
• Market Size 2028
  US$ 1.89 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• MiMedx
• Smith Nephew
• Integra LifeSciences
• Stryker
• Organogenesis
• Katena Products Inc
• NuVision Biotherapies Ltd
• Lucina BioSciences
• Next Biosciences

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Type

• Amniotic Membranes
• Amniotic Suspensions

Application

• Wound Care
• Orthopedics
• Ophthalmology
• Other Applications

End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Other End Users

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Insights - Amniotic Products Market

Rising Incidence of Burn Injuries and Increasing Number of Traumatic Wounds to Drive Amniotic Products Market

According to a 2018 retrospective examination of Medicare users, 8.2 million persons suffered wounds that were infected or not. The cost of acute and chronic wound treatments was estimated to cost between US$ 28.1 billion and US$ 96.8 billion by Medicare. Surgical wounds were the most expensive, followed by diabetic foot ulcers, with the cost of outpatient wound care higher than inpatient wound care. Traumatic wound patients are a significant clinical, social, and economic burden because of the rising healthcare expenditures, an aging population, identification of difficult-to-treat infection risks, such as biofilms, and the global hazard of diabetes and obesity.

Compared to the overall burden of chronic wounds as a health care concern, research funding dedicated to studying chronic wounds is disproportionately low. Wound healing using amniotic membrane grafts has some therapeutic potential. Early use of an amniotic membrane for ulcers, burns, and cutaneous injuries proved therapeutic.

Following are a few examples of companies that launched new products developments and product approvals:

• In June 2021, MiMedx Group, Inc. announced successful regulatory approval from the Japanese Ministry of Health, Labor and Welfare (JMHLW), known to market EPIFIX in Japan. With this approval, the company claims that the geographic expansion will increase revenue and customer bases and ensure the company’s growth.

• In February 2020, AmnioExcel Plus was introduced by Integra LifeSciences Holdings Corporation. It is a novel technology that physicians can use in both the operating room and ambulatory wound care setting to help end the epidemic of approximately 8.2 million wounds with an estimated annual cost to Medicare of up to $98.6 billion fight.

Such product developments by market players are driving the amniotic products market. 

Type-Based Insights - Amniotic Products Market

Based on type, the amniotic products market has been bifurcated into amniotic membranes and amniotic suspensions. The amniotic membranes segment is likely to hold the largest share of the market in 2022.  The amniotic membrane segment growth is growing due to increasing research in stem cell and regenerative medicine, high R&D investments, and an increase in the number of surgeries conducted globally. Further, they are commonly employed in the treatment of bacterial keratitis, corneal ulcers, cataract, glaucoma, bullous keratopathy, corneal degeneration, ocular dystrophy, eyelid reconstruction, and other eye surface problems. The expansion in the world's senior population increases the number of ophthalmology surgeries, , resulting in a growing need for tissue-based products.

Services-Based Insights

Based on application, the global amniotic products market is segmented into wound care, orthopedics, ophthalmology, and other applications. Wound care is a challenging and constantly changing field of medicine. Chronic wounds, in particular, occupy a significant amount of time, effort, and money in the medical community. Due to various factors, including neuropathy, hyperglycemia, infection, and other concurrent disorders, the wounds are more likely to develop chronic.

The human amniotic membrane has been used for nearly a century to treat wounds. Since the early twentieth century, amniotic membrane allografts (AMAs) have been used to treat burns, ulcers, traumatic wounds, surgical incisions, and ocular problems in various medical disciplines. The use of AMAs in treating chronic ulcers is one area where they have acquired a lot of traction. As new preservation techniques and research advances, AMAs have been highly employed in the medical community, particularly in offices and wound care centers. This has also expanded the usage of allografts among physicians who practice non-surgical specialties.

Furthermore, the increasing number of traumatic injuries globally propel the wound care segment. For instance, as per WHO, around 1,000,000 people are severely or moderately burnt annually in India. In addition, as per NCBI, every day, over 30,000 people suffer new burns worldwide, severe enough to warrant medical attention, equating to an estimated 11 million new burns each year globally.

 

Partnerships and collaborations are highly adopted strategies by the global amniotic products market players. A few of the recent key market developments are listed below:

In June 2021, MiMedx Group, Inc. announced the publication of its peer-reviewed study in the Journal of Investigative Dermatology (JID) Innovations, addressing the potential utility of MiMedx Purion-processed human amniotic/chorionic membrane (dHACM) dehydrated in combating complications of excessive fibrosis, a pathological process central to a number of serious unmet medical needs. It is estimated that more than 100 million people worldwide suffer from pathological scarring each year, including hypertrophic and keloid scarring, with long-term effects ranging in severity from minor cosmetic defects to significantly compromised tissue architecture and dysfunction in a range of conditions. Product development and innovation will strengthen the product portfolio in the near future.

Due to widespread lockdowns, denied wound care services, and cancelled or postponed elective surgeries, the COVID-19 outbreak had a negative impact on the amniotic products market in 2020. Elective procedures were denied (cancelled/postponed) in order to allocate or redirect scarce capacities and resources (such as hospital beds and patient care professionals) to COVID-19 patient care. In addition, to combat the increased number of COVID-19 cases, several countries imposed lockdowns and curfews. Patients were unable to visit hospitals, outpatient clinics, or clinics due to the lockdowns. The amniotic products industry is projected to be limited by this temporary suspension of non-emergent healthcare services. However, in the next years, demand for amniotic products is projected to increase.  

Amniotic Products Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Amniotic Products Market Segmentation

The global amniotic products market is analyzed on the basis of type, application, end user, and geography. In terms of type, the market is bifurcated into amniotic membranes and amniotic suspensions. Based on application, the market is segmented into wound care, orthopedics, ophthalmology, and other applications. Based on end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. Geographically, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.  

Company Profiles

• MiMedx        
• Smith & Nephew     
• Integra LifeSciences          
• Stryker       
• Organogenesis        
• Katena Products, Inc.        
• NuVision Biotherapies Ltd   
• Lucina BioSciences            
• Next Biosciences     
• Sanuwave and Sanuwave Health, Inc.